Healthcare policy & drug approvals
Open this topic in the app to listen.
After decades of being legally barred from haggling, the federal government is finally using its massive market share to lower costs. This shift is already forcing global pharmaceutical giants to rewrite their long-term R&D playbooks for the first time in a generation.
Internal documents reveal how regulators overruled their own statisticians to approve a failed Alzheimer's drug, exposing how the 'accelerated approval' pathway has become a controversial industry standard.
Fylom episodes are researched, written, and voiced by AI. Automated checks help catch inaccuracies, but episodes aren't reviewed by a human and AI can still get things wrong. Treat them as a starting point, not a source of record — more in our accuracy disclaimer.